Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 46

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Non-small cell lung cancer

Not yet recruiting

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+1

Not yet recruiting

Evaluation of Lung Function Using Xenon Gas with CT Imaging in Lung and Breast Cancer Patients Receiving Radiotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:XENON (133XE)
  • Sponsor:UZ Brussel

Pulmonary arterial hypertension

Not yet recruiting

Study of gallium-68 FAPI imaging to assess blood vessel changes in patients with pulmonary arterial hypertension receiving sotatercept

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga)
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Post-acute COVID-19 syndrome

Not yet recruiting

A Study of Bevacizumab for Adults with Long-Lasting Breathing Problems After COVID-19 Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Bronchopulmonary aspergillosis

Not yet recruiting

Study of inhaled liposomal amphotericin B and technetium-99m to assess lung distribution in patients with chronic pulmonary aspergillosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Stichting Radboud University Medical Center

Pharyngitis

Not yet recruiting

Study of benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for treating acute pharyngitis symptoms

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:2,4 DICHLOROBENZYL ALCOHOL
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Pulmonary arterial hypertension

Not yet recruiting

Study of calcifediol treatment to improve vitamin D levels in adults with pulmonary arterial hypertension

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpha-Tocopherol
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Non-small cell lung cancer metastatic

Not yet recruiting

Study of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitair Ziekenhuis Gent

Pneumonia bacterial

Not yet recruiting

Safety and tolerability study of bacteriophage cocktail TP-122A given by inhalation in adults with ventilator-associated pneumonia

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Demerecviridae Bacteriophage Against Klebesiella Pneumoniae (113.073 Bp)
  • Sponsor:Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.

Asthma

Not yet recruiting

Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Salmeterol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Non-small cell lung cancer metastatic

Not yet recruiting

Evaluating shorter duration of pembrolizumab and pemetrexed treatment in patients with metastatic non-small cell lung cancer who have not progressed after 6 months

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.